To be assessed every 4 months. 12. Triplicate 12 leads ECGs: At each time point, three consecutive 12 lead ECGs will be performed approximately 2 minutes apart to determine mean QTcF inter val. If the mean QTcF is prolonged (>500 msec), the ECGs should be reevaluated by a qualified person at the institution for confirmation. Additional triplicate ECGs will be performed at Month 12 Day 1, Month 18 Day 1, or may be performed as clinically indicated. 13. Investigational Product Administration: Treatment to be administered after all other assessments required on that day have been performed, including pregnancy test. Al l participants will continue to receive the components to which they were assigned to receive during the treatment period. – note either the tremelimumab or the sasanlimab may be dose reduced or permanently discontinued after discussion with the Sponsor for participants assigned to receive these co mponents. 14.